| 000 | 01628 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250514190047.0 | ||
| 264 | 0 | _c20041228 | |
| 008 | 200412s 0 0 eng d | ||
| 022 | _a1019-6439 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSuyama, Hisashi | |
| 245 | 0 | 0 |
_aERK activation and subsequent RB phosphorylation are important determinants of the sensitivity to paclitaxel in lung adenocarcinoma cells. _h[electronic resource] |
| 260 |
_bInternational journal of oncology _cJun 2004 |
||
| 300 |
_a1499-504 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xdrug therapy |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xpharmacology |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 |
_aEnzyme Activation _xdrug effects |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aExtracellular Signal-Regulated MAP Kinases _xmetabolism |
| 650 | 0 | 4 |
_aG1 Phase _xdrug effects |
| 650 | 0 | 4 | _aGene Expression Regulation, Neoplastic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPaclitaxel _xpharmacology |
| 650 | 0 | 4 |
_aPhosphorylation _xdrug effects |
| 650 | 0 | 4 |
_aRetinoblastoma Protein _xdrug effects |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 700 | 1 | _aIgishi, Tadashi | |
| 700 | 1 | _aSano, Hiroyuki | |
| 700 | 1 | _aMatsumoto, Shingo | |
| 700 | 1 | _aShigeoka, Yasushi | |
| 700 | 1 | _aNakanishi, Hirofumi | |
| 700 | 1 | _aEndo, Masahiro | |
| 700 | 1 | _aBurioka, Naoto | |
| 700 | 1 | _aHitsuda, Yutaka | |
| 700 | 1 | _aShimizu, Eiji | |
| 773 | 0 |
_tInternational journal of oncology _gvol. 24 _gno. 6 _gp. 1499-504 |
|
| 999 |
_c14848000 _d14848000 |
||